Core Insights - The emergence of Nipah virus cases in West Bengal, India, with a mortality rate exceeding 40%, has raised significant concerns [1] - The research published by the Wuhan Institute of Virology indicates that the oral nucleoside drug VV116 shows promising antiviral activity against Nipah virus, providing new hope for treatment [1][2] Group 1: Drug Development - VV116 is a novel oral nucleoside antiviral drug that has been approved for COVID-19 treatment in Uzbekistan and China [3] - In vitro studies demonstrate that VV116 and its active metabolites significantly inhibit Nipah virus, including Malaysian strain NiV-M and Bangladeshi strain NiV-B [3] - In a lethal dose infection model in golden hamsters, VV116 at a dosage of 400 mg/kg increased survival rates to 66.7% and significantly reduced viral loads in target organs such as the lungs, spleen, and brain [3] Group 2: Market Reaction - Following the announcement of VV116's potential against Nipah virus, the stock of its parent company, Wangshan Wangshui (02630.HK), surged over 10% on January 27 [4] - Despite the positive market reaction, VV116 is still in the preclinical research stage and requires human clinical trials, regulatory approval, and market launch before it can be used as a treatment [4] Group 3: Historical Context - Nipah virus is not a new virus, having caused outbreaks in Malaysia, Singapore, India, and Bangladesh since 1998 [4] - The lack of effective vaccines and therapies for Nipah virus over the years is attributed to insufficient funding for research and relatively low case numbers, despite its high mortality rate [4]
旺山旺水新冠口服药有抑制尼帕病毒潜力，但距离应用还很远